These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 4098642)

  • 1. The separation of the substrates for plasma kallikrein and plasmin from a human kininogen.
    Mackay M; Combridge BS
    Br J Exp Pathol; 1970 Aug; 51(4):356-60. PubMed ID: 4098642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin.
    Kleniewski J; Blankenship DT; Cardin AD; Donaldson V
    J Lab Clin Med; 1992 Jul; 120(1):129-39. PubMed ID: 1535355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular forms of plasmin and protease inhibitors in human fibrinolytic post-mortem plasma.
    Müllertz S
    Scand J Clin Lab Invest; 1972 Dec; 30(4):369-79. PubMed ID: 4118172
    [No Abstract]   [Full Text] [Related]  

  • 4. [Purification and some characteristics of a kallikrein from swine serum].
    Habermann E; Klett W
    Biochem Z; 1966 Sep; 346(2):133-58. PubMed ID: 4170318
    [No Abstract]   [Full Text] [Related]  

  • 5. [Purification of kininogen II (LMW) from human plasma].
    Díaz A; Henriques OB
    Acta Physiol Lat Am; 1976; 26(4):243-7. PubMed ID: 1032267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial purification and some properties of high molecular weight kininogen, bovine kininogen-I.
    Yano M; Nagasawa S; Suzuki T
    J Biochem; 1971 Mar; 69(3):471-81. PubMed ID: 4251666
    [No Abstract]   [Full Text] [Related]  

  • 7. Plasma inhibitors of the components of the fibrinolytic pathway in man.
    Schreiber AD; Kaplan AP; Austen KF
    J Clin Invest; 1973 Jun; 52(6):1394-401. PubMed ID: 4122174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Purification and properties of high-molecular-weight rabbit kininogen].
    Egorova TP; Rossinskaia EB; Paskhina TS
    Biokhimiia; 1976 Jul; 41(6):1052-60. PubMed ID: 1027487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of factor XII in plasma from rats pretreated with tranexamic acid. Inhibition of a plasmin-induced loss of the functional activity of high molecular weight kininogen.
    Briseid K; Ryssdal AB
    Acta Pharmacol Toxicol (Copenh); 1980 Sep; 47(3):161-70. PubMed ID: 6449829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of the insulin-like activity of serum. II. Characterization of insulin-like activity of serum protein fractions from normal human subjects.
    Gjedde F
    Acta Endocrinol (Copenh); 1968 Mar; 57(3):478-504. PubMed ID: 4170211
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydrolysis of plasma kallikrein by trypsin and plasmin and the formation of active fragments.
    Sampaio CA; Vidmar S; Hamaguchi A; Sampaio MU
    Adv Exp Med Biol; 1986; 198 Pt B():105-11. PubMed ID: 2949543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of water-insoluble derivatives of the trypsin-kallikrein inhibitor for the isolation of kallikrein and plasmin].
    Fritz H; Brey B; Schmal A; Werle E
    Hoppe Seylers Z Physiol Chem; 1969 May; 350(5):617-25. PubMed ID: 4239805
    [No Abstract]   [Full Text] [Related]  

  • 13. [Studies on the structure of bovine serum kininogen, using cyanogen bromide and carboxypeptidase B].
    Habermann E; Helbig J
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1967; 258(2):160-80. PubMed ID: 4172346
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased activity of plasma and tissue kallikreins, plasma kininase II and salivary kallikrein in pemphigus foliaceus (fogo selvagem).
    Rosatelli TB; Roselino AM; Dellalibera-Joviliano R; Reis ML; Donadi EA
    Br J Dermatol; 2005 Apr; 152(4):650-7. PubMed ID: 15840094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunoassay of human fibrinopeptide B and kinetics of fibrinopeptide cleavage by different enzymes.
    Bilezikian SB; Nossel HL; Butler VP; Canfield RE
    J Clin Invest; 1975 Aug; 56(2):438-45. PubMed ID: 50328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Amino acid makeup, structural characteristics and substrate specificity of rabbit plasma kininogen].
    Egorova TP; Makevnina LG; Paskhina TS
    Biokhimiia; 1975; 40(1):158-65. PubMed ID: 1138995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic pseudocyst fluid--a mixture of plasma proteins and pancreatic juice possessing a high proteolytic activity.
    Lasson A; Göransson J; Ohlsson K
    Scand J Clin Lab Invest; 1989 Sep; 49(5):403-12. PubMed ID: 2531913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human plasma kallikrein. Immunoreactivity and activity on natural and synthetic substrates.
    Motta G; Sampaio CA; Sampaio MU
    Agents Actions Suppl; 1992; 36():200-8. PubMed ID: 1609643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heterogeneity of the high molecular weight B12 binder in serum.
    Lawrence C
    Blood; 1969 Jun; 33(6):899-908. PubMed ID: 4183649
    [No Abstract]   [Full Text] [Related]  

  • 20. Half-periods of serum proteins in the dog.
    Bruenger FW; Stevens W; Stover BJ
    Am J Vet Res; 1967 Nov; 28(127):1699-703. PubMed ID: 4169488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.